论文信息 - Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial - 字舞流文

Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial

A. Rousseau | T. Simon | B. Laviolle | O. Launay | K. Lacombe | C. Chidiac | E. Botelho-Nevers | B. Bienvenu | O. Bouchaud | L. Ninove | O. Epaulard | C. Janssen | P. Loubet | M. Cachanado | J. Michon | Z. Maakaroun-Vermesse | M. Montil | H. Aumaître | L. Berard | M. Lachâtre | C. Schmidt-Mutter | A. Touati | Ady Assaf | T. Boisson | M. Brière | X. D. de Lamballerie | Christine Pereira

[1] D. Montefiori,et al. Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report , 2021, medRxiv.

[2] M. Reitsma,et al. Quantifying and Benchmarking Disparities in COVID-19 Vaccination Rates by Race and Ethnicity , 2021, JAMA network open.

[3] Rosalind J Wright,et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine , 2021, Cell.

[4] L. Heylen,et al. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. , 2021, JAMA.

[5] F. Cosset,et al. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination , 2021, Nature.

[6] V. Libri,et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial , 2021, The Lancet.

[7] H. Emborg,et al. Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose , 2021, medRxiv.

[8] A. Folgori,et al. Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19 , 2021, npj Vaccines.

[9] A. Borobia,et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.

[10] J. Stephenson. Unequal Access to COVID-19 Vaccines Leaves Less-Wealthy Countries More Vulnerable, Poses Threat to Global Immunity. , 2021, JAMA health forum.

[11] B. Kuehn. High-Income Countries Have Secured the Bulk of COVID-19 Vaccines. , 2021, JAMA.

[12] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[13] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[14] P. Gallian,et al. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors , 2020, Antiviral Research.

[15] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.